BNP Paribas Financial Markets Has $24.43 Million Position in Scholar Rock Holding Corporation $SRRK

BNP Paribas Financial Markets boosted its holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 2,628.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 554,602 shares of the company’s stock after acquiring an additional 534,278 shares during the quarter. BNP Paribas Financial Markets’ holdings in Scholar Rock were worth $24,430,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. IFP Advisors Inc lifted its holdings in Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after buying an additional 450 shares during the period. Ramirez Asset Management Inc. acquired a new position in Scholar Rock in the third quarter valued at approximately $37,000. EverSource Wealth Advisors LLC lifted its holdings in Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares during the period. Penserra Capital Management LLC acquired a new position in Scholar Rock in the third quarter valued at approximately $56,000. Finally, Strs Ohio acquired a new position in Scholar Rock in the first quarter valued at approximately $77,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Scholar Rock

In related news, COO Keith Woods sold 10,220 shares of the firm’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $506,605.40. Following the sale, the chief operating officer directly owned 620,055 shares in the company, valued at $30,736,126.35. This trade represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David Hallal sold 30,615 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $1,517,585.55. Following the sale, the chief executive officer owned 1,639,034 shares in the company, valued at approximately $81,246,915.38. The trade was a 1.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 63,491 shares of company stock valued at $3,147,249. Insiders own 13.30% of the company’s stock.

Scholar Rock Trading Down 2.3%

SRRK opened at $44.30 on Friday. The firm’s fifty day moving average is $48.00 and its two-hundred day moving average is $45.63. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. The firm has a market cap of $5.31 billion, a PE ratio of -12.34 and a beta of 0.69. Scholar Rock Holding Corporation has a twelve month low of $27.07 and a twelve month high of $52.19.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same period in the prior year, the business posted ($0.67) EPS. Equities research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Raymond James Financial restated a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday, March 3rd. JPMorgan Chase & Co. increased their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, March 16th. BMO Capital Markets increased their target price on shares of Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, March 4th. Piper Sandler increased their target price on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. Finally, Citigroup increased their target price on shares of Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Four research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $56.00.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).